![Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD | npj Primary Care Respiratory Medicine Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD | npj Primary Care Respiratory Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41533-021-00255-7/MediaObjects/41533_2021_255_Fig1_HTML.png)
Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD | npj Primary Care Respiratory Medicine
![CHEST on X: "Inhalers are not always the most sustainable option for patients with #COPD. The best delivery device depends on various factors, including access to medication, cost and ease of use. CHEST on X: "Inhalers are not always the most sustainable option for patients with #COPD. The best delivery device depends on various factors, including access to medication, cost and ease of use.](https://pbs.twimg.com/media/FvxoB_rX0AM4HTs.png)
CHEST on X: "Inhalers are not always the most sustainable option for patients with #COPD. The best delivery device depends on various factors, including access to medication, cost and ease of use.
![Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPD | Business Wire Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPD | Business Wire](https://mms.businesswire.com/media/20171205006502/en/628179/5/LM_NebulizerSystem.jpg)
Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPD | Business Wire
![Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease | Cleveland Clinic Journal of Medicine Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease | Cleveland Clinic Journal of Medicine](https://www.ccjm.org/content/ccjom/85/2_suppl_1/S19/F1.large.jpg)